Licensing and cell lines
Horizon has agreements in place with several licensors to work with an extensive catalogue of cell line backgrounds. Additionally, we may be able to support clients in accessing further cell lines.
Knock-ins
*Products that have utilised CRISPR Cas9 systems and methodologies to knock-in a gene, and their use, may be the subject of one or more of the following patents and applications controlled by Sigma-Aldrich Co. LLC (SIGMA): Patent applications and issued patents that entered their respective National Stage from PCT International Pub. No. WO 2014/089290, including, but not limited to, the following, and substitutions, divisions, continuations, continuations-in-part, reissues, re-examinations, and extensions thereof: Australia Patent Nos. 2013355214; 2017204031; and 2018229489; Canada Patent Nos. 2,891,347 and 2,977,152; China Patent No. CN105142669; European Patent Nos. EP 2 928 496 B1; EP 3 138 910 B1, 3 138 911 B1, EP 3 138 912 B1, EP 3 360 964 B1, EP 3 363 902 B1; Israel Patent No. IL238856; Singapore Patent No. 11201503824S; South Korea Patent Nos. 10-1844123 and 10-2006880; and U.S. Patent Nos. 10,731,181 and 10,745,716; and U.S. Application Serial Nos. 15/188,927; 15/188,931; and 15/456,204 (the “Patent Rights”).
iPSC editing
Certain drug screening, target validation and toxicity testing methods that utilize in-vitro differentiated disease models may be covered by one or more patents controlled by Evotec International GmbH. Those patents include EP2270196B1, EP1745144B1 and EP3070174B1 and corresponding foreign patents and pending applications. The purchase or transfer of this product is not intended, either expressly or by implication, to grant any right or license to practice under the foregoing patents. Purchasers are advised to contact Evotec International GmbH at info@evotec.com for information regarding a license to practice under such patents.
*Note on inducible cell line projectsHorizon uses the Tet-On 3G inducible expression system for inducible custom engineering projects. This platform is based on the Tet-On® 3G bipartite induction system: a tightly regulated system consisting of an optimized inducible RNA polymerase II promoter (TRE3G), which provides both minimal basal expression and potent activation upon induction with doxycycline. Prior to starting an inducible cell line engineering project, it is the responsibility of the client to provide licensing from Clontech Laboratories for freedom to use this system.
Terms & conditions
All cell line engineering projects are subject to our Terms & Conditions and our Limited Use Label License.